Schweizerhall expands its pharmaceutical market presence with the acquisition of Novosis AG
Luzi A. von Bidder, President of the Board of Directors of Schweizerhall Holding AG states: "The acquisition of Novosis represents an excellent strategic fit and complementary strengthening of our pharmaceutical activities. Hence it broadens our technology base for pharmaceuticals particularly in the area of advanced drug delivery, strengthens our offering for the generics industry and improves our access to research-driven pharmaceutical companies. After this purchase Schweizerhall still has sufficient financial flexibility to fuel the further expansion of the Business Unit Pharma".
Most read news
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.